Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV

July 13, 2021 updated by: Ding Ma, Huazhong University of Science and Technology

Study on Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV

Most uterine cervical high-risk human papillomavirus (HPV) infections are transient, with only a small fraction developing into cervical cancer. Family aggregation studies and heritability estimates suggest a significant inherited genetic component. Candidate gene studies and previous genome-wide association studies (GWASs) report associations between the HLA region and cervical cancer. Adopting a genome-wide approach, we aimed to establish an early warning model for a high-risk population of cervical cancer.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

20000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Ding Ma, MD, PhD
Phone Number: 0086-27-836268
Email: dma@tjh.tjmu.edu.cn

Study Locations

China
- Hubei
  - Wuhan, Hubei, China, 430000
    - Recruiting
    - Tongji Hospital
    - Contact:
      
      Ding Ma, MD
      
      Phone Number: 0086-27-8362681
      
      Email: dma@tjh.tjmu.edu.cn

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Sampling Method

Non-Probability Sample

Study Population

Chinese population

Description

Inclusion Criteria:

(1) Case group a) Aged 25-75 years. b) Han nationality. c) Patients with cervical cancer or cervical precancerous lesions above CIN2 diagnosed by biopsy or postoperative pathological diagnosis.
(2) Control group: a) Aged 25-75 years. b) Han nationality. c) No family history of cervical cancer or precancerous lesions. d) The results of TCT examination showed no abnormality.

Exclusion Criteria:

(1) suffering from other neoplastic diseases.
(2) pregnant women.
(3) those with a history of bone marrow transplantation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Significant loci of genetic variation Time Frame: 2	The impact of genetic variance on predisposition to cervical cancer	2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Huazhong University of Science and Technology

Collaborators

Qilu Hospital of Shandong University

Third Military Medical University

Women's Hospital School Of Medicine Zhejiang University

Shenzhen Second People's Hospital

Obstetrics & Gynecology Hospital of Fudan University

Wuhan Central Hospital

Xiangyang Central Hospital

Investigators

Study Chair: Ding Ma, MD, PhD, Huazhong University of Science and Technology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2021

Primary Completion (Anticipated)

December 1, 2023

Study Completion (Anticipated)

December 1, 2023

Study Registration Dates

First Submitted

June 24, 2021

First Submitted That Met QC Criteria

July 13, 2021

First Posted (Actual)

July 23, 2021

Study Record Updates

Last Update Posted (Actual)